Methods of treating skin disorders using an IL-31RA antagonist

• US 7,871,618 B2
• Filed: 03/13/2009
• Issued: 01/18/2011
• Est. Priority Date: 02/14/2005
• Status: Active Grant

• Current Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Inventors: Bilsborough, Janine
• Primary Examiner(s): Woodward; Cherie M
• Application Number:
  US12/404,162
• Publication Number:
  US 20090252730A1
• Time in Patent Office: 676 Days
• Field of Search: None
• US Class Current: 424/139.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/10 Anti-acne agents
• CPC Class Codes: A61P 17/14 for baldness or alopecia
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/7155 for interleukins [IL]
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

The present invention relates to methods of treating patients suffering from Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination by administering an IL-31RA antagonist.

Claims

1. A method of treating a patient with a condition selected from the group consisting of:

a) prurigo nodularis;

b) Cutaneous T cell Lymphoma;

c) Bullous pemphigoid;

d) Vitiligo;

e) Acne Rosacea; and

f) Scleroderma

the method comprising;

administering a therapeutically effective amount of an anti-IL-31RA antibody or antigen-binding fragment thereof to the patient, wherein the anti-IL-31RA antibody or fragment binds amino acid residues 20-519 of SEQ ID NO;

6.

2. The method of claim 1, wherein the anti-IL-31RA antibody or fragment is a purified mixture of polyclonal antibodies or antigen-binding fragments thereof.

3. The method of claim 1, wherein the anti-IL-31RA antibody or fragment is neutralizing.

4. The method of claim 1, wherein the antigen-binding fragment is a Fab fragment.

5. The method of claim 1, wherein the antigen-binding fragment is a Fab′

fragment.

6. The method of claim 1, wherein the antigen-binding fragment is a F(ab′

)2 fragment.

7. The method of claim 1, wherein the antigen-binding fragment is a single chain Fv.

8. The method of claim 1, wherein anti-IL-31RA antibody or fragment binds amino acid residues 20-277 of SEQ ID NO:

6.

9. The method of claim 1, wherein the antibody or fragment is further conjugated to a polyethylene glycol.

10. The method of claim 1, wherein the antibody or fragment is further conjugated to human serum albumin.

11. A method of treating a patient with prurigo nodularis, the method comprising administering a therapeutically effective amount of an anti-IL-31 RA antibody or antigen-binding fragment thereof to the patient, wherein the anti-IL-31 RA antibody or fragment binds amino acid residues 20-519 of SEQ ID NO:

6.

12. The method of claim 11, wherein the anti-IL-31RA antibody or fragment is neutralizing.

13. The method of claim 11, wherein the antigen-binding fragment is a Fab fragment.

14. The method of claim 11, wherein the antigen-binding fragment is a is a single chain Fv.

15. The method of claim 11, wherein anti-IL-31RA antibody or fragment binds amino acid residues 20-277 of SEQ ID NO:

6.

16. The method of claim 11, wherein the antibody or fragment is further conjugated to a polyethylene glycol.

17. The method of claim 11, wherein the antibody or fragment is further conjugated to human serum albumin.

18. A method of treating a patient with toxic epidermal necrolysis, the method comprising administering a therapeutically effective amount of an anti-IL-31 RA antibody or antigen-binding fragment thereof to the patient, wherein the anti-IL-31RA antibody or fragment binds amino acid residues 20-519 of SEQ ID NO:

6.

19. The method of claim 18, wherein the anti-IL-31RA antibody or fragment is neutralizing.

20. The method of claim 18, wherein the antigen-binding fragment is a Fab fragment.

21. The method of claim 18, wherein the antigen-binding fragment is a is a single chain Fv.

22. The method of claim 18, wherein anti-IL-31 RA antibody or fragment binds amino acid residues 20-277 of SEQ ID NO:

6.

23. The method of claim 18, wherein the antibody or fragment is further conjugated to a polyethylene glycol.

24. The method of claim 18, wherein the antibody or fragment is further conjugated to human serum albumin.